-
Jul 2017
Antigen-Specific T Cell Analysis Reveals That Active Immune Responses to β Cell Antigens Are Focused on a Unique Set of Epitopes.
J ImmunolYang J, Wen X, Xu H, Torres-Chinn N, Speake C, Greenbaum CJ, Nepom GT, Kwok WW -
May 2017
Academic, Foundation, and Industry Collaboration in Finding New Therapies.
N Engl J MedRamsey BW, Nepom GT, Lonial S -
Jan 2017
Rebranding asymptomatic type 1 diabetes: the case for autoimmune beta cell disorder as a pathological and diagnostic entity.
DiabetologiaBonifacio E, Mathieu C, Nepom GT, Ziegler AG, Anhalt H, Haller MJ, Harrison LC, Hebrok M, Kushner JA, Norris JM, Peakman M, Powers AC, Todd JA, Atkinson MA -
Nov 2016
Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes.
Sci ImmunolLong SA, Thorpe J, DeBerg HA, Gersuk V, Eddy J, Harris KM, Ehlers M, Herold KC, Nepom GT, Linsley PS -
Sep 2016
Clinical trial data access: Opening doors with TrialShare.
J Allergy Clin ImmunolAsare AL, Carey VJ, Rotrosen D, Nepom GT -
Aug 2016
Genetically modified human CD4(+) T cells can be evaluated in vivo without lethal graft-versus-host disease.
ImmunologyAli R, Babad J, Follenzi A, Gebe JA, Brehm MA, Nepom GT, Shultz LD, Greiner DL, DiLorenzo TP -
Jul 2016
Obstacles and opportunities for targeting the effector T cell response in type 1 diabetes.
J AutoimmunBuckner JH, Nepom GT -
Jun 2016
Correlation Among Hypoglycemia, Glycemic Variability, and C-Peptide Preservation After Alefacept Therapy in Patients with Type 1 Diabetes Mellitus: Analysis of Data from the Immune Tolerance Network T1DAL Trial.
Clin TherPinckney A, Rigby MR, Keyes-Elstein L, Soppe CL, Nepom GT, Ehlers MR -
May 2016
A Preclinical Consortium Approach for Assessing the Efficacy of Combined Anti-CD3 Plus IL-1 Blockade in Reversing New-Onset Autoimmune Diabetes in NOD Mice.
DiabetesGill RG, Pagni PP, Kupfer T, Wasserfall CH, Deng S, Posgai A, Manenkova Y, Bel Hani A, Straub L, Bernstein P, Atkinson MA, Herold KC, von Herrath M, Staeva T, Ehlers MR, Nepom GT -
Dec 2015
Adult-onset type 1 diabetes patients display decreased IGRP-specific Tr1 cells in blood.
Clin ImmunolChujo D, Nguyen TS, Foucat E, Blankenship D, Banchereau J, Nepom GT, Chaussabel D, Ueno H -
Nov 2015
Biomarkers for antigen immunotherapy in allergy and type 1 diabetes.
Clin ImmunolOdegard JM, Nepom GT, Wambre E -
Aug 2015
Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients.
J Clin InvestRigby MR, Harris KM, Pinckney A, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Keyes-Elstein L, Long SA, Kanaparthi S, Lim N, Phippard D, Soppe CL, Fitzgibbon ML, McNamara J, Nepom GT, Ehlers MR -
May 2015
Functional inflammatory profiles distinguish myelin-reactive T cells from patients with multiple sclerosis.
Sci Transl MedCao Y, Goods BA, Raddassi K, Nepom GT, Kwok WW, Love JC, Hafler DA -
May 2014
Avidity-dependent programming of autoreactive T cells in T1D.
PLoS OneDurinovic-Belló I, Gersuk VH, Ni C, Wu R, Thorpe J, Jospe N, Sanda S, Greenbaum CJ, Nepom GT -
May 2014
Restoring the balance: immunotherapeutic combinations for autoimmune disease.
Dis Model MechSmilek DE, Ehlers MR, Nepom GT
